Karin Garming-Legert

Karin Garming-Legert

Telefon: +46852488071
Besöksadress: Alfred Nobels Allé 8, 14104 Huddinge
Postadress: OF Odontologi, OF Oral diagnostik och kirurgi, 171 77 Stockholm

Om mig

  • After completing the study program in nursing (1987) and the study program in
    dentistry (1993), I worked as a hospital dentist and clinical teacher at
    Karolinska Institutet with special interest in oral medicine. In 2019 I
    became a specialist in orofacial medicine. I undertook my PhD education at
    Karolinska Institutet and defended my thesis in 2011. The title
    was ​"Conditioning associated effects on oral mucosa and salivary
    secretion in allogeneic stem cell recipients", supervised by Professor Göran
    Dahllöf, Professor Anders Heimdahl and Professor Olle Ringdén. Since around
    2000, I have been a lecturer at the Department of Dental Medicine and have
    since 2012 focused on oral medicine and clinical oral pathology education of
    dental, dental hygienist and continuing professional education dentists. In
    2015, I was appointed as Program Director for the study programs in Dentistry
    and the Complementary Program for Dentists outside EU/EES and Switzerland. I
    have since then been heavily involved in the development and implementation
    of the new dental program study plan. Alongside my teaching and mentoring
    activities for the undergraduate education, I am supervisor for several
    students in the dental Specialist Training Program, as well as supervisor for
    PhD candidates.
    Member of Pedagogiska Akademin, Karolinska Institutet
    Specialist in Orofacial Medicine, 2019
    PhD in Medical Science, 2011
    Study program in Dentistry, 1993
    Study program in Nursing, 1987


  • Current research focuses on developing pathological diagnostics and
    understanding disease processes in the soft tissues of the oral cavity. We
    are concerned with the complications that result following hematopoietic cell
    transplantation in the form of Graft versus Host Disease (GVHD). Oral
    manifestations are one of the most common and debilitating complications with
    the histopathology poorly understood, particularly associated with
    long-standing chronic (c)GVHD. Our ongoing studies are working to understand
    oral mucosal and salivary gland cGVHD pathogenesis, clinical and diagnostic
    criteria and the search for predictive biomarkers.
    Additional, studies are examining other debilitating chronic oral
    complications after high-dose chemotherapy and/ or stem cell transplantation,
    for example the necessity for transfusion of platelets before invasive dental
    procedures and the development of surgical techniques in patients treated
    with bisphosphonates.
    We also aim to find out more about the pathogenesis and clinical pattern of
    different oral mucosal lesions as, white snuff induced oral lesions, aphthous
    stomatitis and oral manifestations in patients suffering from inflammatory
    bowel disease, where we strive to progress the management. Currently we are
    doing a screening study of the dental status in patients with X-linked
    *Research group*
    Rachael Sugars (PI)
    Karin Garming-Legert
    Maria Bankvall
    Victor Tollemar (Doctoral Student)
    Helena Arvidsson (Doctoral Student)
    Nikolce Tudzarovski
    *Original publications*
    1) Efficacy of a novel device for cryoprevention of oral mucositis: a
    randomised, blinded, multicentre, parallel group, phase 3 trial. Java
    Walladbegi, Roger Henriksson, Björn Tavelin, Anncarin Svanberg, Gunnar
    Larfors, Martin Jädersten, Fredrik Schjesvold, Aram Mahdi, *Karin
    Garming-Legert*, Douglas E Peterson, Mats Jontell. Bone Marrow
    Transplant. 2022
  • 57(2):191-197
    2) *Karin Garming Legert*, Olle Ringdén, Mats Remberger, Johan Törlén,
    Jonas Mattsson, Göran Dahllöf. Oral mucositis after
    tacrolimus/sirolimus or cyclosporine/methotrexate as graft-versus-host
    disease prophylaxis. Oral Dis. 2020 Oct 4. doi: 10.1111/odi.13663. Online
    ahead of print.
    3) Tollemar, V
  • Tudzarovski, N
  • Warfvinge, G
  • Yarom, N
  • Remberger, M

  • Heymann, R
  • *Garming-Legert, K*
  • Sugars, RV. Histopathological Grading of
    Oral Mucosal Chronic Graft-versus-host Diseease: Large Cohort Analysis.
    Biology of blood and marrow transplantation: journal of the American
    Sociaty for Blood and Marrow Transplantation. 2020
  • 26(10): 1971-1979
    4) Erik Boberg, Lena von Bahr, Gabriel Afram, Carina Lindström, Per
    Ljungman, Nina Heldring, Peter Petzelbauer, *Karin Garming Legert*, Nadir
    Kadri and Katarina Le Blanc. Treatment of Chronic GvHD with Mesenchymal
    Stromal Cells Induces Durable Responses
  • a Phase II Study. Stem Cells
    Transl Med. 2020 Oct
  • 9(10):1190-1202. doi: 10.1002/sctm.20-0099. Epub
    2020 Jun 23. PMID: 32573983
    5) Tove Kamsvåg [1], Anncarin Svanberg [2], *Karin Garming Legert*
    [3], Johan Arvidson [4], Louise von Essen [5], Karin Mellgren
    [6], Jacek Toporski [7], Jacek Winiarski [8] &
  • Gustaf Ljungman [9].
    Prevention of oral mucositis with cryotherapy in children undergoing
    hematopoietic stem cell transplantations—a feasibility study and
    randomized controlled trial. Support Care Cancer. 2020
  • 28(10):4869-4879. doi: 10.1007/s00520-019-05258-2. Epub 2020 Jan 28.
    PMID: 31993753
    6) Berglund S, Watz E, Remberger M, *Garming Legert K*, Axdorph-Nygell U,
    Sundin M, Uhlin M, Mattsson J. Granulocyte transfusions could benefit
    patients with severe oral mucositis after allogeneic hematopoietic stem
    cell transplantation. Vox Sang. 2019 Oct
  • 114(7):769-777. doi:
    10.1111/vox.12835. Epub 2019 Aug 11.PMID: 31402469
    7) Tollemar V, Tudzarovski N, Boberg E, Törnqvist Andrén A, Al-Adili A, Le
    Blanc K, *Garming Legert K*, Bottai M, Warfvinge G, Sugars R.
    Quantitative Chromogenic Immunohistochemical Image Analysis in
    CellProfiler Software. Cytometry A. 2018 Oct
  • 93(10):1051-1059. doi:
    8) Brennan M, Hasséus B, Hovan A, Raber-Durlacher JE, Blijlevens N,
    Huysmans MC, *Legert KG*, Johansson JE, Moore CG, von Bültzingslöwen I.
    Research Protocol: Multicenter Study to Establish the Impact of Oral Side
    Effects from Conditioning Therapy Before Hematopoietic Stem Cell
    Transplantation “Ora-Stem Study”. JMIR Research Protocols 2018
  • 7(4):
    e103 doi:10.2196/resprot.8982
    9) Toxicological effects of fludarabine and treosulfan conditioning before
    allogeneic stem-cell transplantation. [10] Remberger M, Törlen J, Serafi
    IE, *Garming-Legert K*, Björklund A, Ljungman P, Sundin M, Hassan M,
    Mattsson J. Int J Hematol. 2017 Oct
  • 106(4):471-475
    10) A prospective randomized trial comparing cyclosporine/methotrexate and
    tacrolimus/sirolimus as graft-/versus/-host disease prophylaxis after
    allogeneic hematopoietic stem cell transplantation. Törlén J, Ringdén
    O, *Garming-Legert K*, Ljungman P, Winiarski J, Remes K,
    Itälä-Remes M, Remberger M, Mattsson J. Haematologica 2016

  • 101(11):1417-1425
    11) The relationship between oral mucositis and levels of pro-inflammatory
    cytokines in serum and in gingival crevicular fluid in allogeneic stem
    cell recipients. *Garming Legert Karin, * Tsilingaridis G, Remberger
    Mats, Ringdèn Olle, Heimdahl Anders Yucel-Lindberg, Tülay, Dahllöf
    Göran. JSSC 2015 23:6 1749-57. Doi:1007/s00520-014-2538-z
    12) Activated innate lymphoid cells are associated with a reduced
    susceptibility to graft versus host disease. Marius J. Munneke, Andreas
    T. Bjorklund, Jenny M. Mjosberg, *Karin Garming-Legert*, Jochem H.
    Bernink, Bianca Blom, Cynthia Huisman, Marinus H.J. van Oers, Hergen
    Spits, Karl-Johan Malmberg, and Mette D. Hazenberg. Blood 2014
  • 5:
    13) Reduced intensity conditioning and oral care measures prevent oral
    mucositis and reduces days of hospitalization in allogeneic stem cell
    transplantation recipients. *Karin Garming Legert*, Mats Remberger, Olle
    Ringdén, Anders Heimdahl, Göran Dahllöf. JSCC 2014
  • 22: 2133–2140
    14) A prospective randomized toxicity-study comparing reduced-intensity
    conditioning and myeloablative conditioning in patients with myeloid
    leukemia undergoing allogeneic hematopoietic stem cell transplantation.
    Olle Ringdén, Tom Erkers, Johan Aschan, *Karin Garming-Legert*,
    Katarina Le Blanc, Hans Hägglund, Brigitta Omazic, Petter Svenberg,
    Göran Dahllöf, Jonas Mattsson, Per Ljungman and Mats Remberger. J
    Intern Med. 2013
  • 274: 153-162
    15) Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine
    with or without methotrexate in patients undergoing allogeneic
    haematopoietic stem cell transplantation for non-malignant disorders.
    Ringdén O, Remberger M, Dahllöf G, *Garming-Legert K*, Karlsson H,
    Svenberg P et al European Journal of Haematology 2011
  • 87: 503–509
    16) Improved survival after allogeneic hematopoietic stem cell
    transplantation in recent years. A single-center study. [11] Remberger
    M, Ackefors M, Berglund S, Blennow O, Dahllöf G, Dlugosz A,
    *Garming-Legert* K, et al Biol Blood Marrow Transplant. 2011
  • 17(11):1688-97
    17) Xerostomia in children and adolescents after stem cell transplantation
    conditioned with total body irradiation or busulfan. [12] Dahllöf G,
    Wondimu B, Barr-Agholme M, *Garming-Legert* K, Remberger M, Ringdén O.
    Oral Oncol. 2011 Sep
  • 47(9):915-9
    18) Long-term salivary function after conditioning with busulfan,
    fractionated or single dose TBI. *Garming Legert K*, Ringdén O,
    Remberger M, Heimdahl A, Dahllöf G. Oral Dis. 2011 Oct
  • 17(7):670-6
    19) Salivary secretion after fractionated or single dose total body
    irradiation. *Garming Legert* K, Remberger M, Ringdèn O, Heimdahl A,
    Dahllöf G.Bone Marrow Transplant. 2012 Mar
  • 47(3):404-10
    20) Development and characterisation of an animal model of dental sinusitis.
    *Garming Legert K*, Melén I, Heimdahl A, Stierna P. Acta Otolaryngol.
  • 125(11):1195-1202
    *Review articles*
    1) Basic oral care for haematology–oncology patients and haematopoietic
    stem cell transplantation recipients: a position paper from the joint
    task force of the Multinational Association of Supportiv e Care in
    Cancer/International Society of Oral Oncology (MASCC/ISOO) and the
    European Group for Blood and Marrow Transplantation (EBMT). Elad S,
    Raber-Durlacher J, Brennan M, Saunders D, Mank A, Zadik Y, Quinn B,
    Epstein J, Blijlevens N, Waltimo T, Passweg J, Correra E, Dahllöf G,
    *Garming Legert K* et al. JSCC 2015 Jan
  • 23(1):223-36. doi:
    10.1007/s00520-014-2378-x. Epub 2014 Sep 5.
    2) Sinusitis of periodontal or periapical origin - Pathophysiological
    implications for early treatment. *Garming Legert K*, Zimmerman M,
    Stierna P. Acta Otolaryngol 2004
  • 124: 655-663
    *Letters to the editor*
    1) Stromal Progenitor Cell Modulation by Thalidomide in the Treatment of
    Oral Chronic Graft versus Host Disease. Davies L, Emma Board-Davies,
    Shamlou B, Boberg E, *Garming Legert K*, Le Blanc K. Cytotherapy, 2018

  • 20: 755-758
    2) Enhanced oral healing following local mesenchymal stromal cell therapy.
    *Karin Garming-Legert*, Gregory Tour, Rachael Sugars, Lena von Bahr,
    Lindsay C. Davies, Katarina Le Blanc. Oral Onkology 2015
  • 51(12): E97-E98
    [1] https://link.springer.com/article/10.1007/s00520-019-05258-2#auth-1
    [2] https://link.springer.com/article/10.1007/s00520-019-05258-2#auth-2
    [3] https://link.springer.com/article/10.1007/s00520-019-05258-2#auth-3
    [4] https://link.springer.com/article/10.1007/s00520-019-05258-2#auth-4
    [5] https://link.springer.com/article/10.1007/s00520-019-05258-2#auth-5
    [6] https://link.springer.com/article/10.1007/s00520-019-05258-2#auth-6
    [7] https://link.springer.com/article/10.1007/s00520-019-05258-2#auth-7
    [8] https://link.springer.com/article/10.1007/s00520-019-05258-2#auth-8
    [9] https://link.springer.com/article/10.1007/s00520-019-05258-2#auth-9
    [10] https://www.ncbi.nlm.nih.gov/pubmed/28849374
    [11] http://www.ncbi.nlm.nih.gov/pubmed/21620989
    [12] http://www.ncbi.nlm.nih.gov/pubmed/21784697


  • *Pedagogical profile*
    Orofacial medicine with focus on oral mucosal lesions and conditions, as well
    as acute and chronic oral complications after high-dose chemotherapy and/or
    stem cell transplantation.
    *Pedagogical expertise*
    * Subject Lead in Orofacial Medicine, dept of Dental Medicine
    * Program Director Dental Education
    * Program Director Complementary Education for Dentists from Outside EU/EES
    and Switzerland
    * Chair of the Working Group for the development of the new Dental Education
    Study Plan - implemented August 2019
    * Chair of the Program Committee for the Dental eEducation
    * Chair of the Examination Board for the Dental Education
    * Member of the Working Group for the development of the Study Plan for the
    Dental Specialist Training Program in Orofacial Medicine - implemented
    January 2020
    *Current teaching activities*
    /Dental Undergrade Education/
    * Course Leader for Healthy and Diseased Mouth (2TL058 – 3 hp)
    * Course Leader for Orofacial Medicine 1 (2TL063 – 3 hp)
    * Course Leader for Orofacial Medicine 3
    * Lecturer in Orofacial Medicine and Clinical Oral Pathology
    * Supervision of exam degree projects
    /Dental Hygienist Education/
    * Module Responsible and Lecturer in Orofacial Medicine (1TY014 – 1, 5 hp)
    /Postgraduate education/
    * Lecturer in Orofacial medicine
    * Clinical supervisor in Orofacial Medicine
    * Supervisor in Master and Doctoral education.


Alla övriga publikationer


  • Adjunkt/Övertandläkare, Odontologi, Karolinska Institutet, 2019-

Examina och utbildning

  • Medicine Doktorsexamen, Institutionen för odontologi, Karolinska Institutet, 2011

Nyheter från KI

Kalenderhändelser från KI